# Evaluation of the Vasoconstriction Properties of MC2-01 Cream

> **NCT03758365** · PHASE1 · COMPLETED · sponsor: **MC2 Therapeutics** · enrollment: 36 (actual)

## Conditions studied

- Vasoconstriction

## Interventions

- **DRUG:** MC2-01 Cream
- **DRUG:** Clobetasol Propionate 0.05% Lotion
- **DRUG:** Betamethasone Dipropionate 0.05% Cream
- **DRUG:** Triamcinolone Acetonide 0.1% Cream
- **DRUG:** Hydrocortisone Butyrate 0.1% Cream
- **DRUG:** Desonide 0.05% Cream
- **DRUG:** Vehicle

## Key facts

- **NCT ID:** NCT03758365
- **Lead sponsor:** MC2 Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-05
- **Primary completion:** 2018-11-23
- **Final completion:** 2018-11-23
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2020-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03758365

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03758365, "Evaluation of the Vasoconstriction Properties of MC2-01 Cream". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03758365. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*